BOCA RATON, Fla.—Breckenridge Pharmaceutical Inc. announced Aug. 9 that it had entered into an agreement to acquire from PernixTherapeutics certain assets of its subsidiary, CypressPharmaceuticals, for $30 million.
Breckenridge to acquire certain assets of Cypress for $30 million
Assets include 11 ANDAs filed with the FDA, certain other ANDAs in various stages of development and seven previously marketed products
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
About the Author
This person does not yet have a bio.View Full Profile
Here are some related topics that may interest you:
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Rapid DNA-to-mRNA workflows help scientists keep pace with rapidly evolving cancer through personalized vaccines.
Understand how a human-relevant in vitro model can be used to improve next generation risk assessment (NGRA).
Explore the role of microphysiological systems in advancing human-relevant liver toxicity testing and mechanistic evaluation.
